STOCK TITAN

Integra Lifesciences Hldgs Cp - IART STOCK NEWS

Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global leader in medical technology, headquartered in Plainsboro, New Jersey. Established in 1989, Integra is dedicated to reducing uncertainty for surgeons, allowing them to focus on providing outstanding patient care. The company offers innovative solutions in various medical fields including orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.

Integra's diverse portfolio includes products for regenerative therapy, extremity orthopedics, and neurosurgical applications. Their orthopedic product line features devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. The company is also a key player in the neurosurgery market, offering a broad range of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neurotrauma, and critical care.

Integra operates through two main segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment generates the majority of the company's revenue, focusing on neurosurgical and surgical instrumentation. The Tissue Technologies segment covers regenerative and advanced wound care products.

With over 3,500 employees worldwide, Integra serves markets in Europe, the Asia-Pacific region, and other parts of the globe, although the bulk of its revenue comes from domestic sales. Recently, the company announced its second-quarter 2023 financial results, highlighting a total revenue of $381.3 million, a slight decline compared to the previous year, primarily due to a recall issue at their Boston manufacturing facility. Despite this, the company showed resilience with strong performances in certain product lines and updated their guidance for 2023 revenue and earnings per share.

Integra's recent acquisition of Acclarent, a leader in ENT procedures, for $275 million, showcases their ongoing commitment to expanding their product offerings and improving healthcare outcomes. This acquisition is expected to close by the second quarter of 2024 and will significantly bolster Integra's position in the ENT market.

Integra continues to develop and launch groundbreaking products such as the CereLink ICP Monitoring System for intracranial pressure monitoring and the MicroMatrix Flex, which addresses complex wound reconstruction needs. These innovations reflect Integra's dedication to advancing surgical, neurologic, and regenerative care standards.

For the latest updates and further information, visit www.integralife.com.

Rhea-AI Summary

Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced its preliminary fourth quarter and full-year 2020 revenue results. The fourth quarter revenue is estimated between $387 million to $389 million, marking a decrease of up to 2.1% year-over-year. Full-year revenue is projected at $1,370 million to $1,372 million, reflecting a 9.7% decline. Despite these figures, the company indicated sequential improvement from Q3 and anticipates growth in 2021 following its recent divestiture of Extremity Orthopedics and acquisition of ACell. Financial results will be fully released on February 18, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
-
Rhea-AI Summary

Integra LifeSciences (NASDAQ:IART) has finalized the divestiture of its Extremity Orthopedics business to Smith+Nephew. This strategic move aims to enhance Integra's focus on its core offerings in neurosurgery and regenerative medicine. CEO Peter Arduini emphasized that this divestiture will help create greater value for customers and shareholders. The company is advised by Piper Sandler & Co. as financial advisor and Morgan, Lewis & Bockius LLP as legal advisor. Future performance remains uncertain, with various risks noted, including financial performance projections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
none
-
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced that CEO Peter Arduini will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 8:20 AM ET. The presentation will be accessible via a live webcast on the company’s investor relations website. Integra specializes in regenerative technologies and neurosurgical solutions, aiming to enhance patient care through its extensive portfolio of products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
conferences
Rhea-AI Summary

Integra LifeSciences has announced the acquisition of ACell for $300 million, with additional payments of up to $100 million based on revenue milestones. This strategic move reinforces Integra's regenerative medicine capabilities, particularly in tissue technologies. ACell's proprietary products, including MatriStem UBM™, will be integrated into Integra's existing offerings, enhancing its portfolio. In 2019, ACell reported revenues of $100.8 million, showing 13% growth. The acquisition is expected to be accretive to revenue growth and adjusted gross margins, with a neutral impact on adjusted EBITDA margin and earnings per share in the first year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
-
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (IART) reported third-quarter 2020 revenues of $370.2 million, down 2.3% year-over-year but up 43.1% sequentially. GAAP earnings per diluted share were $0.38, reversing a loss from the prior year. Adjusted net income increased to $67.7 million, or $0.80 per share. The company maintained a strong financial position with $396 million in cash. However, full-year 2020 guidance remains withdrawn due to COVID-19 uncertainties impacting surgical volumes. Management expects further revenue improvement in Q4, barring significant pandemic setbacks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
-
Rhea-AI Summary

Integra LifeSciences (NASDAQ: IART) reported preliminary third quarter revenue of $368 to $370 million, indicating a 2.7% decline year-over-year. This organic revenue decline of 1.8% is a significant recovery from the 32.6% decrease in the second quarter. The results surpassed the company's earlier outlook and showed broad-based sales improvements across its major franchises. Full financial results will be released on October 28, 2020, along with a conference call for further insights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.29%
Tags
Rhea-AI Summary

Integra LifeSciences (NASDAQ: IART) has announced its participation in two upcoming investor conferences in September 2020. Carrie Anderson, the CFO, will present at the Wells Fargo 2020 Virtual Healthcare Conference on September 10 at 9:20 AM ET, followed by CEO Peter Arduini at the Morgan Stanley Virtual Global Healthcare Conference on September 14 at 10:30 AM ET. Both presentations will be webcasted on the company’s investor relations website. Integra is a leader in regenerative technologies and aims to enhance patient care through its comprehensive product portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
none
-
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (IART) reported second-quarter revenues of $258.7 million, down 32.6% year-over-year, mainly due to COVID-19's impact on surgical procedures. The company reported a GAAP loss per diluted share of ($0.00) compared to $0.34 in Q2 2019. Adjusted earnings per diluted share fell to $0.33 from $0.73. Gross margins also declined, with GAAP margins at 59.2%. Despite challenges, revenue showed sequential improvement, and the company ended the quarter with $361 million in cash. Full-year guidance remains withdrawn due to ongoing uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
-
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (Nasdaq:IART) has received FDA clearance for its CUSA® Clarity Ultrasonic Surgical Aspirator System, specifically for neurosurgery. This system is now indicated for the safe and effective resection of tumors, including malignant and benign types, marking a significant advancement in neurosurgical technology. The CUSA system has over 40 years of clinical use and is noted for its ability to enhance surgical outcomes. The launch aligns with Glioblastoma Awareness Day, highlighting the importance of this technology in treating aggressive brain tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
Rhea-AI Summary

Integra LifeSciences (NASDAQ: IART) announced preliminary second quarter 2020 revenue results, estimating revenues between $254 million and $256 million, reflecting a 34% decline from 2019. Despite improving monthly sales due to lifted COVID-19 restrictions, June sales were down approximately 15% from the previous year's second quarter. The company will share full financial results on August 10, 2020, and acknowledges ongoing uncertainty regarding future revenue impacts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags

FAQ

What is the current stock price of Integra Lifesciences Hldgs Cp (IART)?

The current stock price of Integra Lifesciences Hldgs Cp (IART) is $23.21 as of February 28, 2025.

What is the market cap of Integra Lifesciences Hldgs Cp (IART)?

The market cap of Integra Lifesciences Hldgs Cp (IART) is approximately 1.8B.

What does Integra LifeSciences Holdings Corp. specialize in?

Integra specializes in innovative medical technologies for orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.

Where is Integra LifeSciences headquartered?

Integra LifeSciences is headquartered in Plainsboro, New Jersey.

What are the primary segments of Integra LifeSciences?

Integra operates through two primary segments: Codman Specialty Surgical and Tissue Technologies.

What recent acquisition was announced by Integra LifeSciences?

Integra recently announced the acquisition of Acclarent, Inc. for $275 million, expected to close by the second quarter of 2024.

What are some of the key products offered by Integra LifeSciences?

Key products include CereLink ICP Monitoring System, MicroMatrix Flex, and a range of implants and devices for neurosurgery and orthopedic procedures.

How did Integra perform financially in the second quarter of 2023?

Integra reported total revenues of $381.3 million, with certain product lines demonstrating strong organic growth despite a recall impacting their Boston facility.

What is the purpose of Integra’s CereLink ICP Monitoring System?

The CereLink ICP Monitoring System provides advanced continuous monitoring of intracranial pressure, essential for managing patients with traumatic brain injuries and other neurological conditions.

How many employees does Integra LifeSciences have?

Integra LifeSciences has over 3,500 employees worldwide.

Which markets does Integra LifeSciences serve?

Integra serves markets in Europe, the Asia-Pacific region, and other global areas, with significant revenue from domestic sales.

What is Integra’s strategy for growth in 2024?

Integra aims to enhance quality and reliability in manufacturing, advance their product pipeline, and integrate the Acclarent acquisition to drive revenue growth and operational performance.
Integra Lifesciences Hldgs Cp

Nasdaq:IART

IART Rankings

IART Stock Data

1.79B
66.19M
14.25%
93.07%
4.37%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PRINCETON